Department of Physiology and Pharmacology, Wake Forest School of Medicine, Winston-Salem, North Carolina (M.M., P.W.C., M.A.N.) and Discovery Sciences, Research Triangle Institute, Research Triangle Park, North Carolina (B.E.B.).
Department of Physiology and Pharmacology, Wake Forest School of Medicine, Winston-Salem, North Carolina (M.M., P.W.C., M.A.N.) and Discovery Sciences, Research Triangle Institute, Research Triangle Park, North Carolina (B.E.B.)
J Pharmacol Exp Ther. 2020 Jul;374(1):1-5. doi: 10.1124/jpet.120.264952. Epub 2020 Apr 8.
Stimulant abuse is a persistent public health problem with no Food and Drug Administration-approved pharmacotherapy. Although monoamine-releasing drugs such as -amphetamine can decrease cocaine self-administration in human and animal laboratory studies, their potential for abuse limits clinical utility. "Abuse-deterrent" formulations of monoamine releasers, such as prodrugs, hold greater clinical promise if their abuse potential is, as theorized, lower than that of cocaine. In these studies, we determined the reinforcing strength of phendimetrazine (PDM), a prodrug for the amphetamine-like monoamine releaser phenmetrazine; both drugs have been shown to decrease cocaine self-administration in laboratory animals. To date, no study has directly compared PDM (Schedule III) with cocaine (Schedule II) under progressive-ratio (PR) schedules of reinforcement, which are better suited than fixed-ratio schedules to directly compare reinforcing strength of drugs. Dose-response curves for cocaine (saline, 0.001-0.3 mg/kg per injection) and PDM (0.1-1.0 mg/kg per injection) were generated in six cocaine-experienced male rhesus monkeys during 4-hour sessions with a 20-minute limited hold (LH). Under these conditions, the maximum number of injections was not significantly different between cocaine and PDM. The reinforcing strength of doses situated on the peaks of the cocaine and PDM dose-effect curves were redetermined with a 60-minute LH. The mean number of injections increased for both drugs, but not for saline. Cocaine presentations resulted in significantly higher peak injections than PDM with a 60-minute LH, which is consistent with the lower scheduling of PDM. These results support PDM as Schedule III and highlight the importance of schedule parameters when comparing reinforcing strength of drugs using a PR schedule of reinforcement. SIGNIFICANCE STATEMENT: One strategy for reducing cocaine use is to identify a treatment that substitutes for cocaine but has lower abuse potential. In a rhesus monkey model of drug abuse, this study compared the reinforcing strength of cocaine and phendimetrazine, a drug that has been shown to decrease cocaine use in some studies.
兴奋剂滥用是一个长期存在的公共卫生问题,目前还没有获得美国食品和药物管理局批准的药物治疗方法。虽然单胺释放药物,如苯丙胺,可减少人类和动物实验室研究中的可卡因自我给药,但它们的滥用潜力限制了其临床应用。如果像理论上那样,单胺释放剂的“滥用防御”制剂,如前药的滥用潜力低于可卡因,那么它们具有更大的临床应用前景。在这些研究中,我们确定了苯丁胺(PDM)的强化作用,苯丁胺是一种类似于苯丙胺的单胺释放剂苯甲曲嗪的前药;这两种药物都已被证明可减少实验室动物中的可卡因自我给药。迄今为止,尚无研究直接比较 PD(附表 III)与可卡因(附表 II)在递增比例(PR)强化时间表下的情况,PR 时间表比固定比例时间表更适合直接比较药物的强化作用。在 4 小时的会议中,在 20 分钟的有限保留(LH)期间,用可卡因(盐水,0.001-0.3mg/kg/次)和 PDM(0.1-1.0mg/kg/次)给 6 只可卡因经验丰富的雄性恒河猴生成剂量反应曲线。在这些条件下,可卡因和 PDM 剂量-效应曲线峰值上的剂量的最大注射次数没有显着差异。用 60 分钟的 LH 重新确定了位于可卡因和 PDM 剂量效应曲线峰值上的剂量的强化强度。两种药物的注射次数均增加,但盐水组没有增加。与 60 分钟 LH 相比,可卡因的呈现导致峰值注射量显着增加,这与 PD 的低调度一致。这些结果支持 PD 为附表 III,并强调了在使用 PR 强化时间表比较药物的强化作用时,时间表参数的重要性。意义陈述:减少可卡因使用的一种策略是确定一种替代可卡因但滥用潜力较低的治疗方法。在滥用药物的恒河猴模型中,本研究比较了可卡因和苯丁胺的强化作用,苯丁胺在一些研究中已被证明可减少可卡因的使用。